Not all sufferers with CLL demand therapy. In spite of all modern improvements, the iwCLL even now recommends watchful observation for patients with asymptomatic illness.86 This recommendation is predicated on no less than two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (